reports
- Emmanuel Matot
- Marc Lavaud
- Michael B. Schäfer
- Marc Lavaud
- Michael B. Schäfer
- Damien Choplain
- Martial Descoutures
Novartis : Reassuring CMD on the medium to long-term outlook
>Prefer quality over quantity - At its CMD in London yesterday, Novartis confirmed its pure player positioning in innovative medicine and its strategy focused on four therapeutic areas (cardiovascular/renal, oncology, neuroscience and immunology), five technological platforms and four geographical regions (US, China, Germany, Japan). We note the ambition to continue to improve R&D productivity by reducing the time-to-market (in part thanks to the use of AI) and focus...
- Damien Choplain
- Martial Descoutures
Novartis : CMD rassurant sur les perspectives MT/LT
>Privilégier la qualité à la quantité - Dans le cadre de son CMD qui s’est tenu hier à Londres, Novartis a confirmé son positionnement pure player médecine innovante et sa stratégie centrée sur 4 aires thérapeutiques (cardiovasculaire/rénal, oncologie, neuroscience et immunologie), 5 plateformes technologiques et 4 zones géographiques (US, Chine, Allemagne, Japon). Nous notons une volonté de continuer à améliorer la productivité de la R&D en réduisant le time-to-mark...
Moody's Ratings assigns A3 rating to Gilead's notes; stable outlook
Moody's Ratings (Moody´s) assigned an A3 rating to the new senior unsecured notes issuance of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing ratings including the A3 senior unsecured ratings, (P)A3 senior unsecured shelf or the stable outlook. Proceeds of the offering ...
Gilead Sciences Inc: 2 directors
Two Directors at Gilead Sciences Inc sold/sold after exercising options 30,590 shares at between 91.280USD and 91.500USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...
- Oliver Metzger
WCH WACKER CHEMIE AG
GALP GALP ENERGIA SGPS SA CLASS B
ADS ADIDAS AG
NOVN NOVARTIS AG
FORTUM FORTUM OYJ
ALV ALLIANZ SE
ISP INTESA SANPAOLO S.P.A.
SIX2 SIXT SE
UCG UNICREDIT S.P.A.
BP. BP P.L.C.
DWS DWS GROUP GMBH & CO. KGAA
8TRA TRATON SE
STMN STRAUMANN HOLDING AG
- Oliver Metzger
WCH WACKER CHEMIE AG
GALP GALP ENERGIA SGPS SA CLASS B
ADS ADIDAS AG
NOVN NOVARTIS AG
FORTUM FORTUM OYJ
ALV ALLIANZ SE
ISP INTESA SANPAOLO S.P.A.
SIX2 SIXT SE
UCG UNICREDIT S.P.A.
BP. BP P.L.C.
DWS DWS GROUP GMBH & CO. KGAA
8TRA TRATON SE
STMN STRAUMANN HOLDING AG
- Damien Choplain
- Martial Descoutures
Novartis : Q3 ahead of expectations – FY guidance upgraded
>Excellent performance from flagship products - Q3 came in ahead of expectations for revenues (+2% vs consensus) and core EPS (+6% vs consensus). Sales grew 10% cc (9% reported), driven by all the flagship products: Entresto (26% cc, -1% vs cons.), Cosentyx (28% cc, +8% vs cons.), Kisqali (43% cc, +1% vs cons.), Kesimpta (28%, +1% vs cons.) and Pluvicto (50% cc, +2% vs cons.). We note that c. 60% of the beat stems from the excellent performance from Cosentyx driven by...
- Damien Choplain
- Martial Descoutures
Novartis : T3 2024 au-dessus des attentes. Guidance FY relevée
>Excellente performance des produits phares - Le T3 ressort au-dessus des attentes au niveau des ventes (+2% vs Css) et du core BPA (+6% vs Css). Les ventes progressent de 10% tcc (9% en publié) tirées par tous les produits phares : Entresto (26%cc, -1% vs Cs), Cosentyx (28%cc, +8% vs Cs), Kisqali (43%cc, +1% vs Cs) et Kesimpta (28%cc, +1% vs Cs) et Pluvicto (50%cc, +2% vs Cs). Soulignons que c. 60% du beat provient de l’excellente performance de Cosentyx tiré par les...
- Team Pharma
ODDO : Feedback from the MS Expert Access event: still many areas for ...
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the a...
- Team Pharma
ODDO : Feedback Expert Access SEP : encore de nombreux axes d’améliora...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage acc...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 October 2024 in which we reassessed the appropriateness of the ratings in the cont...
- Bruno Cavalier
- Jean Danjou
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/14/2024
We are removing GSK from our European Large Caps Convictions List. The company is the only one of the six Big Pharma groups to have experienced a break in trend, which could act as a drag on future publications. Our analyst adjusted this morning his EPS estimates for 2024/2025/2026 by -0.6%, 2.0% and- 3.4% respectively, factoring in weaker growth for Arexvy and Shingrix, hence the lowering of his target price from 2,150p to 1,900p. - ...
CA CARREFOUR SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
ROG ROCHE HOLDING LTD
ORA ORANGE SA
NOVN NOVARTIS AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
SAND SANDVIK AB
EN BOUYGUES SA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SAN SANOFI
HEI HEIDELBERGCEMENT AG
AIR AIRBUS SE
01913 PRADA S.P.A.
MOCORP METSO OUTOTEC OYJ
FDR FLUIDRA S.A.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
AZN ASTRAZENECA PLC
ASML ASML HOLDING NV
EPI A EPIROC AB
GSK GSK PLC
NOVO B NOVO NORDISK A/S
- Bruno Cavalier
- Jean Danjou
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/10/2024
Nous sortons GSK de notre liste de valeurs recommandées Large Caps. La société est la seule des 6 big Pharma à connaître une rupture de tendance qui pourrait peser lors des prochaines publications. Notre analyste ajuste ce jour ses prévisions de BPA 24/25/26 de -0.6%/-2.0%/-3.4% intégrant une plus faible croissance pour Arexvy et Shingrix, ce qui conduit à une baisse de son objectif de cours de 2 150p à 1 900p. - ...
CA CARREFOUR SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
ROG ROCHE HOLDING LTD
ORA ORANGE SA
NOVN NOVARTIS AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
SAND SANDVIK AB
EN BOUYGUES SA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SAN SANOFI
HEI HEIDELBERGCEMENT AG
AIR AIRBUS SE
01913 PRADA S.P.A.
MOCORP METSO OUTOTEC OYJ
FDR FLUIDRA S.A.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
AZN ASTRAZENECA PLC
ASML ASML HOLDING NV
EPI A EPIROC AB
GSK GSK PLC
NOVO B NOVO NORDISK A/S
- Team Pharma
ODDO : Confirmation of guidance ahead of a busy Q4 for clinical result...
>Adverse trend in September - The pharma sector’s stock market performance in Q3 fell short of the momentum seen in the first half of the year (large cap pharma coverage at -7.7% vs Stoxx 600 HC at -0.4%). Indeed, after a sector rally over the summer (July and August), several stocks came under pressure in September. Unlike the previous quarter, AstraZeneca, Novo Nordisk and Roche took a hit (-12.7%, -16% and -5.8% respectively) after the disappointing clinical perfo...
- Team Pharma
ODDO : Confirmation des guidances avant un T4 cliniquement dense
>Un mois de septembre pénalisant - La performance boursière du secteur pharma au T3 a été en-deçà de la dynamique enregistrée sur la première moitié de l’année (coverage large cap pharma -7.7% vs Stoxx 600 HC -0.4%). En effet, après un rebond sectoriel durant l’été (juillet et août), nous avons observé une pression sur plusieurs titres au mois de septembre. Contrairement au trimestre passé, AstraZeneca, Novo Nordisk et Roche ont été fortement pénalisées (-12.7%, -16% ...
- Dave Nicoski
- Ross LaDuke
ULTA ULTA BEAUTY INC
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MLAB MESA LABORATORIES INC.
KRC KILROY REALTY CORPORATION
HAIN HAIN CELESTIAL GROUP INC.
GDOT GREEN DOT CORPORATION CLASS A
FIVE FIVE BELOW INC.
EXPE EXPEDIA GROUP INC.
EGBN EAGLE BANCORP INC.
CF CF INDUSTRIES HOLDINGS INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BRKL BROOKLINE BANCORP INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
ALGN ALIGN TECHNOLOGY INC.
WY WEYERHAEUSER COMPANY
DRI DARDEN RESTAURANTS INC.
FMC FMC CORPORATION
THS TREEHOUSE FOODS INC.
TR TOOTSIE ROLL INDUSTRIES INC.
VFC V.F. CORPORATION
ASIX ADVANSIX INC.
PFE PFIZER INC.
CSCO CISCO SYSTEMS INC.
CTVA CORTEVA INC
CPRI CAPRI HOLDINGS LIMITED
GL GLOBE LIFE INC.
ASO ACADEMY SPORTS AND OUTDOORS
CZR CAESARS ENTERTAINMENT INC
CHK CHESAPEAKE ENERGY CORP
NYMT NEW YORK MORTGAGE TRUST INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.